Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8227734 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 8 Pages |
Abstract
At least partly through promoting cell growth, EZH2 implicates disease progression, confers tumor aggressiveness, and represents an independent adverse prognosticator in patients with NPC.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Chung-Feng M.D., Hsuan-Ying M.D., Chang-Han Ph.D., Chih-Yen M.D., Yao-Chung M.D., Chien-Feng M.D., Fu-Min M.D., Ph.D.,